Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock ...

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

This educational supplement is based on a press release statement from Neurocrine Biosciences and aims to enhance clinical practice and patient care for those affected by classic CAH. According to ...

SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has sponsored a supplement in The Journal of Clinical Endocrinology & Metabolism (JCEM) focusing on classic congenital adrenal hyperplasia (CAH), ...

Oppenheimer reiterated its Outperform rating on Neurocrine Biosciences, highlighting the FDA approval of Crenessity for the treatment of congenital adrenal hyperplasia (CAH) as a pivotal event.

Analysts are closely monitoring how this competition might impact Neurocrine's revenue growth and market position in the coming years. The recent approval of Crenessity for adult and pediatric ...

Crenessity, a CAH treatment by Neurocrine, was also launched recently but analysts believe CRNX has a very good opportunity to differentiate itself as a better product, helping its marketing ...

Crenessity, a CAH treatment by Neurocrine, was also launched recently but analysts believe CRNX has a very good opportunity to differentiate itself as a better product, helping its marketing ...